NEW YORK, Nov. 06, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and Instil Bio, Inc (NASDAQ: UNTIL). Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

After the market closed on October 21, 2022, Accelerate Diagnostics announced that it has received a request from the U.S. Food and Drug Administration that the Company cease marketing and distribution of its Accelerate Arc System and associated BC- to immediately discontinue kits for a specific diagnostic use.

Accelerate Diagnostics previously marketed the Accelerate Arc products as Class I devices and exempted them from 510(k) clearance requirements. The FDA recently informed the company that marketing the products in the United States requires 510(k) clearance.

Accelerate Diagnostics shares are down about 9% in premarket trading and more than 40% in intraday trading on October 24, 2022.

For more information on how Accelerate Diagnostics investigates, see: https://bespc.com/cases/AXDX

Instil Bio, Inc. (NASDAQ:BIS)

The investigation focuses on whether the company made false and/or misleading statements and/or failed to disclose information relevant to investors. Instil Bio announced on October 31, 2022 that it had notified the FDA that it had voluntarily suspended enrollment in a clinical trial due to manufacturing issues with one of its therapies. Manufacturing issues meant that patients in a clinical trial of ITIL-168 for advanced melanoma could not be properly dosed.

On the news, shares of Instil Bio fell more than 33% in intraday trading.

For more information on the Instil investigation, visit: